What's in a Label? Radioimmunotherapy for metastatic prostate cancer.
Prostate cancer has a highly tumor-restricted prostate-specific membrane antigen (PSMA) and may be the ideal solid-organ malignancy for treatment with radioimmunotherapy. Encouraging results using lutetium-177-labeled anti-PSMA monoclonal antibody J591 from a phase II study by Tawaga and colleagues support the continued clinical and preclinical development of radioimmunotherapy for solid tumors.
Authors' Affiliation: Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Charles B
CB
Simone
Stephen M
SM
Hahn
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D043425:Glutamate Carboxypeptidase II / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000532:radiotherapy*; D016499:Radioimmunotherapy
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D000970:Antineoplastic Agents; C478680:J591 monoclonal antibody; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II